مختصر البحث:
This study was contributed to assess clinical outcomes related to the role of biologic therapies, targeted therapies, regenerative medicine, and novel
drug development in the treatment of rheumatology patients. Patients and methods: A cross-section…
This study was contributed to assess clinical outcomes related to the role of biologic therapies, targeted therapies, regenerative medicine, and novel
drug development in the treatment of rheumatology patients. Patients and methods: A cross-sectional study of 80 rheumatology different hospitals
in Iraq analyzed demographic and clinical data from February 2022 to September 2023. The study included 80 cases who underwent modern
treatments and methods within the disease management program. The patients were categorized into remission, low, moderate, and high disease
severity. Common symptoms included joint pain, swelling, decreased range of motion, fatigue, muscle weakness, fever, numbness, skin rash, weight
loss, and difficulty with daily activities. Treatment data included corticoids, cDMARD, bDMARD, and cDMARD combined bDMARD. The study also
assessed patients' quality of life, ranging from 0 to 100, based on physical function, psychological function, emotional and social aspects, and daily
activity. A multivariate analysis of risk factors affecting patients with rheumatic diseases was performed. Results: Our results shown that males
were 16 cases and females were 64 cases, the smoking rate were 30%, obesity was 50%, hypertension was 80%, diabetes was 55%, and
cerebrovascular disease was 30%, and the most common symptoms of rheumatic disease which distribute into patients swelling and tenderness in
the joints was 80%, joint pain, and stiffness was 85%, and fatigue was 60%, types of treatments used in patients with rheumatology which contain
corticoids included 8 cases, cDMARD included 56 cases, bDMARD included 4 cases, and cDMARD combined bDMARD included 12 cases, and we
identify activity rheumatic disease which classified into remission got 36 cases, low got 20 cases, moderate got 16 cases, and high got 8 cases.
Conclusion: Patients with rheumatic diseases have benefited from biological therapies, targeted therapies, regenerative medicine, and novel drug
development.
